Literature DB >> 22238321

Alpha interferon and HIV infection cause activation of human T cells in NSG-BLT mice.

Brian R Long1, Cheryl A Stoddart.   

Abstract

The development of small animal models for the study of HIV transmission is important for evaluation of HIV prophylaxis and disease pathogenesis. In humanized bone marrow-liver-thymus (BLT) mice, hematopoiesis is reconstituted by implantation of human fetal liver and thymus tissue (Thy/Liv) plus intravenous injection of autologous liver-derived hematopoietic stem progenitor cells (HSPC). This results in reconstitution of human leukocytes in the mouse peripheral blood, lymphoid organs, and mucosal sites. NOD-scid interleukin-2 receptor-negative (IL-2Rγ(-/-)) (NSG)-BLT mice were inoculated intravaginally with HIV and were monitored for plasma viremia by a branched DNA assay 4 weeks later. T-cell activation was determined by expression of CD38 and HLA-DR on human CD4(+) and CD8(+) T cells in mouse peripheral blood at the time of inoculation and 4 weeks later. Additional BLT mice were treated with human alpha interferon 2b (IFN-α2b) (intron A) and assessed for T-cell activation. Productive HIV infection in BLT mice was associated with T-cell activation (increases in CD38 mean fluorescence intensity and both the frequency and absolute number of CD38(+) HLA-DR(+) T cells) that correlated strongly with plasma viral load and was most pronounced in the CD8(+) T-cell compartment. This T-cell activation phenotype was recapitulated in NSG-BLT mice treated with intron A. HIV susceptibility correlated with the number of HSPC injected, yet a number of mice receiving the Thy/Liv implant alone, with no HSPC injection, were also susceptible to intravaginal HIV. These results are consistent with studies linking T-cell activation to progressive disease in humans and lend support for the use of NSG-BLT mice in studies of HIV pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22238321      PMCID: PMC3302309          DOI: 10.1128/JVI.06676-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

Review 1.  Microarray data on gene modulation by HIV-1 in immune cells: 2000-2006.

Authors:  Malavika S Giri; Michael Nebozhyn; Louise Showe; Luis J Montaner
Journal:  J Leukoc Biol       Date:  2006-08-29       Impact factor: 4.962

2.  Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1.

Authors:  Michael W Melkus; Jacob D Estes; Angela Padgett-Thomas; Joel Gatlin; Paul W Denton; Florence A Othieno; Anja K Wege; Ashley T Haase; J Victor Garcia
Journal:  Nat Med       Date:  2006-10-22       Impact factor: 53.440

3.  Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation.

Authors:  Ping Lan; Noriko Tonomura; Akira Shimizu; Shumei Wang; Yong-Guang Yang
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

4.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.

Authors:  S D Der; A Zhou; B R Williams; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 5.  Type I interferon production in HIV-infected patients.

Authors:  Anne Hosmalin; Pierre Lebon
Journal:  J Leukoc Biol       Date:  2006-08-17       Impact factor: 4.962

6.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Authors:  Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

7.  Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.

Authors:  Z Liu; W G Cumberland; L E Hultin; H E Prince; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-10-01

8.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.

Authors:  J V Giorgi; L E Hultin; J A McKeating; T D Johnson; B Owens; L P Jacobson; R Shih; J Lewis; D J Wiley; J P Phair; S M Wolinsky; R Detels
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

Review 9.  Assay of human stem cells by repopulation of NOD/SCID mice.

Authors:  J E Dick; M Bhatia; O Gan; U Kapp; J C Wang
Journal:  Stem Cells       Date:  1997       Impact factor: 6.277

10.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

Authors:  Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

View more
  32 in total

Review 1.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

2.  APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.

Authors:  John F Krisko; Nurjahan Begum; Caroline E Baker; John L Foster; J Victor Garcia
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  Minocycline attenuates HIV-1 infection and suppresses chronic immune activation in humanized NOD/LtsZ-scidIL-2Rγ(null) mice.

Authors:  Maneesh Singh; Pratibha Singh; Dolores Vaira; Mathieu Amand; Souad Rahmouni; Michel Moutschen
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

4.  Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque.

Authors:  Cheryl A Stoddart; Sofiya A Galkina; Pheroze Joshi; Galina Kosikova; Mary E Moreno; Jose M Rivera; Barbara Sloan; Aaron B Reeve; Stefan G Sarafianos; Michael Murphey-Corb; Michael A Parniak
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

Review 5.  HIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters.

Authors:  Sho Sugawara; David L Thomas; Ashwin Balagopal
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-15       Impact factor: 2.205

Review 6.  New generation humanized mice for virus research: comparative aspects and future prospects.

Authors:  Ramesh Akkina
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

Review 7.  Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis.

Authors:  LiGuo Zhang; Eric Meissner; JianZhu Chen; LiShan Su
Journal:  Sci China Life Sci       Date:  2010-03-07       Impact factor: 6.038

8.  Tissue-specific interferon alpha subtype response to SIV infection in brain, spleen, and lung.

Authors:  Luna Alammar Zaritsky; Alicia Dery; Wan Yee Leong; Lucio Gama; Janice E Clements
Journal:  J Interferon Cytokine Res       Date:  2012-10-10       Impact factor: 2.607

Review 9.  Humanized mice for immune system investigation: progress, promise and challenges.

Authors:  Leonard D Shultz; Michael A Brehm; J Victor Garcia-Martinez; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

10.  Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Authors:  Daniel T Claiborne; Timothy E Dudek; Colby R Maldini; Karen A Power; Musie Ghebremichael; Edward Seung; Elizabeth F Mellors; Vladimir D Vrbanac; Katharine Krupp; Abigail Bisesi; Andrew M Tager; David M Knipe; Christian L Boutwell; Todd M Allen
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.